Document is current
Any future updates will be listed below
-
Authors
Kyte, J. A. https://orcid.org/0000-0002-2854-3694
Andresen, N. K.
Russnes, H. G.
Fretland, S. Ø.
Falk, R. S.
Lingjærde, O. C.
Naume, B.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03409198 at ClinicalTrials.govDocuments that mention this clinical trial
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
https://doi.org/10.1186/s12967-020-02421-w
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
https://doi.org/10.1136/jitc-2023-007990
-
Funding
Funding for this research was provided by:
Helse Sør-Øst RHF (2018090, 2017100)
Bristol-Myers Squibb Foundation
- License Information
-
More Information
Article History
Received: 18 April 2020
Accepted: 17 June 2020
First Online: 3 July 2020
Ethics approval and consent to participate
: The ICON trial has been approved by the Norwegian and Belgian Medical Agencies and Ethics Committees. The study is performed in compliance with the World Medical Association Declaration of Helsinki and ICH E6 for Good Clinical Practice. Signed informed consent is obtained from all patients.
: All authors have consented to the publication. Approval has also been obtained from BMS.
: The authors declare that they have no competing interests.
